EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Efficacy and safety of risankizumab in paediatric patients with psoriasis in the OptIMMize-1 phase III study

Nina Magnolo, Lara Wine Lee, Adam Reich, Irene Lara-Corrales, Akimichi Morita, Michael Bukhalo, Asunción Vicente, Toni Anschutz, Rosie D Lyles, Tshepiso Madihlaba, Kristina Unnebrink, Doug Ashley, Dolly Sharma, Ronilda D’Cunha, Amy S Paller

British Journal of Dermatology · 2026-09-26

DOI: 10.1093/bjd/ljag403 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Treatment options for paediatric patients with psoriasis are limited, and additional, more advanced therapies are needed. Risankizumab is an interleukin-23 inhibitor approved to treat moderate-to-severe psoriasis in adults. Objectives To evaluate efficacy and safety of risankizumab through 52 weeks in paediatric patients with moderate-to-severe psoriasis. Methods OptIMMize-1 (Clinical Trial Registration NCT04435600) was a phase III, multicentre, four-part study. Parts 1, 3 and 4 were 52-week, open-label studies. Part 2 consisted of a 16-week initial treatment period (Period A; 2 : 1 risankizumab: ustekinumab randomization), followed by up to 36-week randomized treatment or withdrawal period (Period B) for patients whose disease responded to risankizumab, with a potential 16-week retreatment period (Period C) for patients who experienced a disease flare. Patients whose disease did not respond to risankizumab and patients randomized to ustekinumab in Period A received risankizumab during Period B. Key outcomes were a static Physician’s Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1), sPGA 0 or 1 with ≥ 2-grade improvement (sPGA 0/1 + ≥ 2GI) or achievement of ≥ 75%, ≥ 90% or 100% improvement in Psoriasis Area and Severity Index (PASI 75/90/100). The study also assessed itch severity, quality of life and safety. Results A total of 137 patients enrolled. In Part 2 (risankizumab, n = 54; ustekinumab, n = 28), week 16 response rates were similar: sPGA 0/1 was 80% (n = 43/54) for risankizumab and 75% (n = 21/28) for ustekinumab; sPGA 0/1 + ≥ 2GI rates were 69% (n = 37/54) vs. 68% (n = 19/28); PASI 75 rates were 85% (n = 46/54) vs. 86% (n = 24/28); and PASI 90 rates were 65% (n = 35/54) vs. 61% (n = 17/28). PASI 100 responses were higher with risankizumab (41%, n = 22/54) than with ustekinumab (18%, n = 5/28). In Part 4 (n = 30), week 16 rates were sPGA 0/1: 90% (n = 27/30), sPGA 0/1 + ≥ 2GI: 83% (n = 25/30), PASI 75: 87% (n = 26/30), PASI 90: 77% (n = 23/30) and PASI 100: 43% (n = 13/30); week 52 responses were maintained or improved. Skin clearance outcomes in Parts 1 and 3 were consistent with those observed with continuous risankizumab treatment in Parts 2 and 4. Improvements in itch and quality of life (assessed in Part 2 only) were observed at weeks 16 and 52. Risankizumab safety profiles were consistent with those observed in prior adult psoriasis studies. Conclusions Risankizumab was well tolerated in paediatric patients, with marked improvements in skin clearance, itching and quality of life. Efficacy was maintained or improved at week 52, supporting risankizumab use for moderate-to-severe psoriasis in this population.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →